In order to expand its presence in the ophthalmic pharmaceutical eye drop space, Alcon has entered into a definitive merger agreement with Aerie Pharmaceuticals through which Alcon will acquire Aerie for US$15.25 per share. The transaction, worth approximately US$770 M, will provide Alcon with access to two marketed glaucoma medicines, Rhopressa® and Rocklatan®, as well as a pipeline of experimental therapies. Since early 2021, Alcon hasalso acquired the US rights to Novartis’ glaucoma eye drop, Simbrinza®, as well as two products from Kala Pharmaceuticals that treat dry eye disease and post-surgical inflammation.